Shikha Singla, MD

MCW
Fox Point, Wisconsin, United States

111200

Presentation(s):

• 0585: Fungal Infections, Including Candida, in Patients With Active Axial Spondyloarthritis Treated With Secukinumab: A Pooled Analysis of 10 Phase 3 Trials

  Sunday, October 26, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Terminated); Johnson and Johnson: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Prometheus Biosciences: Grant/Research Support (Ongoing); UCB: Consultant (Ongoing)

• 1459: Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials

  Monday, October 27, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Terminated); Johnson and Johnson: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Prometheus Biosciences: Grant/Research Support (Ongoing); UCB: Consultant (Ongoing)

• 2375: Ixekizumab Provided Rapid Improvements in Quality of Life and Disease Activity in Patients with Psoriatic Arthritis: Findings from a Real-World Study in the United States of Patients Initiating Ixekizumab or Interleukin-23 Inhibitors

  Tuesday, October 28, 2025
  10:30 AM - 12:30 PM Central Time

  Disclosure(s): AbbVie/Abbott: Consultant (Ongoing), Grant/Research Support (Ongoing); Eli Lilly: Grant/Research Support (Terminated); Johnson and Johnson: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Prometheus Biosciences: Grant/Research Support (Ongoing); UCB: Consultant (Ongoing)